We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.10 | 0.25% | 40.70 | 41.00 | 41.25 | 41.80 | 40.00 | 40.40 | 612,822 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -21.13 | 123.29M |
From May 2022 to May 2024
By Joe Hoppe
Futura Medical PLC shares rose Wednesday after it said it has submitted a full response to the U.S. Food and Drug Administration's questions on its MED3000 gel formulation for the treatment of erectile dysfunction.
Shares at 0847 GMT were up 4.45 pence, or 10% at 46.95 pence.
The pharmaceutical company said is has also sent the requested confirmatory data, which together with the response, has been resubmitted to enable the FDA to continue its review of MED3000.
The company had said on March 14 that the FDA has asked additional questions and requested some nonclinical confirmatory data related to its application for marketing authorization for MED3000.
"Based on the FDA's published target review period guidelines which includes time to review the newly provided information, the board continue to anticipate grant of the... request in [the second quarter of] 2023," the company said.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
March 29, 2023 05:06 ET (09:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
